NCT06557967Completed
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment
Prevalence of Brain Metastases and Impact on Survival in Metastatic Non-small Cell Lung Cancer by Line of Treatment
Source: ClinicalTrials.gov · Last updated 9 Dec 2024
Brief summary (registry, in English)
This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 22517 (actual)
- First submitted
- 14 Aug 2024
- Start date
- 1 Mar 2024
- Primary completion date
- 28 Jun 2024
- Lead sponsor
- Daiichi Sankyo
- Diseases
- Lung cancer
- NCT number
- NCT06557967
What you commit to
- Study type: Observational
- Participants enrolled: 22517
- From 1 Mar 2024 to the primary completion date, 28 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Evidence of other primary malignancy in the 365-day baseline period immediately prior to the first mNSCLC diagnosis in the study period
- Evidence of stereotactic radiosurgery (SRS), stereotactic radiation therapy (SRT), or whole brain radiotherapy (WBRT) in the baseline period
Who the study is looking for
- Diagnosis of mNSCLC in study period (01/01/2015-06/30/2023) including newly diagnosed at metastatic stage or progression from advanced stage NSCLC
- Age 18+ years at the time of diagnosis of mNSCLC
- Additional inclusion criteria for 1st Line of Therapy cohort:
- Treated with systemic anti-cancer therapy in 1L setting
- Additional inclusion criteria for 2nd Line of Therapy and 3rd Line of Therapy cohorts:
- Treated with systemic anti-cancer therapy in 2L setting treated with systemic anti-cancer therapy in 3L setting
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ConcertAI Database Coordinator of this site? Confirm its status | Cambridge | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.